Loading...
Market
FDA safety warning for Ascendis Pharma's YORVIPATH by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements or press releases
Story
FDA Approves Ascendis Pharma's YORVIPATH for Hypoparathyroidism; Stock Rises 10% Post-Takeda
Aug 12, 2024, 11:40 AM
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma's YORVIPATH® (Palopegteriparatide), marking it as the first and only treatment for hypoparathyroidism in adults. This approval positions YORVIPATH as the sole available treatment for this rare hormone disorder in the United States, following the discontinuation of Takeda's previous therapy. The announcement led to a 10% increase in Ascendis Pharma's stock price in premarket trading.
View original story
Similar markets
FDA Approval • 25%
EMA Approval • 25%
Phase 4 Trial Initiation • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
